You are here: Industry Insights > lung cancer

News List

EU approves first-line use of AZ’ Tagrisso in lung cancer pharmatimes
July 10, 2018
AstraZeneca’s Tagrisso has been given a green light in Europe for first-line use to treat EGFR-mutated non-small cell lung cancer (NSCLC), offering a new line of attack at this stage of the disease.
CR UK tests Asterias’ novel lung cancer immunotherapy jab pharmatimes
July 10, 2018
Cancer Research UK has begun testing a novel immunotherapy vaccine for lung cancer in Phase I trials, under a collaboration agreement with Asterias Biotherapeutics.
NICE deems MSD’s Keytruda cost-effective as first-line lung cancer therapy pharmatimes
July 06, 2018
MSD’s Keytruda will be available on the NHS for specific patients with previously untreated metastatic non-small-cell lung cancer, after NHS England struck a deal with the company, endorsed by NICE, to ensure its cost-effectiveness.
With latest data, has Roche's Tecentriq found a blockbuster lung cancer niche? fiercepharma
June 26, 2018
So far, Roche’s Tecentriq hasn’t been able to find a piece of the lung cancer market to call its own. But that may change after its latest trial win.
Forget Tagrisso's $3B sales target. It'll be worth double that by 2023, analyst says fiercepharma
June 26, 2018
Recent approvals of Tagrisso in the first-line lung cancer setting have AstraZeneca management optimistic about the $3 billion sales target it set several years ago. But some analysts have higher hopes—and one just came up with a bullish estimate that's o
AstraZeneca receives EU nod for lung cancer drug Tagrisso biospectrumasia
June 13, 2018
Tagrisso is a monotherapy for the 1st-line treatment of adult patients with locally-advanced or metastatic non-small cell lung cancer
J&J partners with Boston University to tackle lung cancer pharmatimes
June 13, 2018
Johnson & Johnson Innovation has launched a five-year partnership with Boston University to develop new solutions for the prevention, interception and curing of lung cancer.
Aduro starts Phase 1b trial of its immunotherapy treatment for lung cancer pharmaceutical-technology
June 13, 2018
Immunotherapy company Aduro Biotech has announced it has initiated its Phase 1b study of its ADU-214 drug in combination with nivolumab to treat advanced metastatic non-small cell lung cancer.
Roche's breast, lung cancer offerings fail to impress at ASCO pharmafile
June 07, 2018
Roche made an underwhelming impact at the American Society of Clinical Oncology (ASCO) annual event in Chicago, after revealing data which demonstrated only mediocre efficacy for two of its therapies for breast and lung cancer.
Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it? fiercepharma
June 05, 2018
Bristol-Myers Squibb’s new strategy In lung cancer relies on showing its new biomarker can help predict who benefits most from immunotherapy combinations.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page